Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation

被引:14
|
作者
Aziz, N. [1 ,2 ]
Sokoloff, A. [2 ]
Kornak, J. [3 ]
Leva, N. V. [4 ]
Mendiola, M. L. [5 ]
Levison, J. [5 ]
Feakins, C. [6 ]
Shannon, M. [7 ]
Cohan, D. [2 ]
机构
[1] Stanford Univ, Dept Obstet & Gynecol, Sch Med, Stanford, CA 94305 USA
[2] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA USA
[3] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA
[4] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[5] Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA
[6] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Posit Hlth Program, San Francisco, CA USA
[7] Univ Hawaii Manoa, Sch Nursing & Dent Hyg, Honolulu, HI 96822 USA
基金
美国国家卫生研究院;
关键词
Highly active antiretroviral therapy; HIV; pregnancy; pregnant women; suppression; viral load; TO-CHILD TRANSMISSION; ADHERENCE; RECOMMENDATIONS; INTERVENTIONS; DYNAMICS;
D O I
10.1111/1471-0528.12226
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
ObjectiveTo compare time to achieve viral load<400copies/ml and <1000copies/ml in HIV-infected antiretroviral (ARV) -naive versus ARV-experienced pregnant women on highly active antiretroviral therapy (HAART). DesignRetrospective cohort study. SettingThree university medical centers, USA. PopulationHIV-infected pregnant women initiated or restarted on HAART during pregnancy. MethodsWe calculated time to viral load<400copies/ml and <1000copies/ml in HIV-infected pregnant women on HAART who reported at least 50% adherence, stratifying based on previous ARV exposure history. Main outcome measuresTime to HIV viral load<400copies/ml and <1000copies/ml. ResultsWe evaluated 138 HIV-infected pregnant women, comprising 76 ARV-naive and 62 ARV-experienced. Ninety-three percent of ARV-naive women achieved a viral load<400copies/ml during pregnancy compared with 92% of ARV-experienced women (P=0.82). The median number of days to achieve a viral load<400copies/ml in the ARV-naive cohort was 25.0 (range 3.5-133; interquartile range 16-34) days compared with 27.0 (range 8-162.5; interquartile range 18.5-54.3) days in the ARV-experienced cohort (P=0.02). In a multiple predictor analysis, women with higher adherence (adjusted relative hazard [aRH] per 10% increase in adherence 1.29, 95% confidence interval [CI] 1.08-1.54, P=0.01) and receiving a non-nucleotide reverse transcriptase inhibitor (NNRTI) -based regimen (aRH 2.48, 95% CI 1.33-4.63, P=0.01) were more likely to achieve viral load<400copies/ml earlier. Increased baseline HIV log(10) viral load was associated with a later time of achieving viral load<400copies/ml (aRH 0.60, 95% CI 0.39-0.92, P=0.02). In a corresponding model of time to achieve viral load<1000copies/ml, adherence (aRH per 10% increase in adherence 1.79, 95% CI 1.34-2.39, P<0.001), receipt of NNRTI (aRH 2.95, 95% CI 1.23-7.06, P=0.02), and CD4 cell count (aRH per 50 count increase in CD4 1.12, 95% CI 1.03-1.22, P=0.01) were associated with an earlier time to achieve viral load below this threshold. Increasing baseline HIV log(10) viral load was associated with a longer time of achieving viral load<1000copies/ml (aRH 0.54, 95% CI 0.34-0.86, P=0.01). In multiple predictor models, previous ARV exposure was not significantly associated with time to achieve viral load below thresholds of <400copies/ml and <1000 copies/ml. ConclusionsPregnant women with 50% adherence, whether ARV-naive or ARV-experienced, on average achieve a viral load<400copies/ml within a median of 26days and a viral load of<1000copies/ml within a median of 14days of HAART initiation. Increased adherence, receipt of NNRTI-based regimen and lower baseline HIV log(10) viral load were all statistically significant predictors of earlier time to achieve viral load<400copies/ml and <1000copies/ml. Increased CD4 count was statistically significant as a predictor of earlier time to achieve viral load<1000copies/ml.
引用
收藏
页码:1534 / 1547
页数:14
相关论文
共 50 条
  • [1] Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women
    Patel, Deven
    [J]. CLINICAL INFECTIOUS DISEASES, 2007, 44 (12) : 1647 - 1656
  • [2] Antiretroviral therapy for pregnant HIV-infected women
    Luber, AD
    Dong, BJ
    [J]. ANNALS OF INTERNAL MEDICINE, 2000, 132 (06) : 509 - 509
  • [3] VIRAL SUPPRESSION IN LATE PRESENTING HIV-INFECTED PREGNANT WOMEN
    Xavier-Souza, E.
    Nobrega, I.
    Limbo, M. S.
    Barone, C.
    Fernandes, S.
    Nello, E.
    Travassos, A. G.
    [J]. SEXUALLY TRANSMITTED INFECTIONS, 2017, 93 : A120 - A121
  • [4] Intensification of antiretroviral treatment with raltegravir for late-presenting HIV-infected pregnant women
    Thepnarong, N.
    Puthanakit, T.
    Chaithongwongwatthana, S.
    Anugulruengkitt, S.
    Anunsittichai, O.
    Theerawit, T.
    Pancharoen, C.
    Phanuphak, P.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2017, 20 : 59 - 59
  • [5] Hospitalizations of pregnant HIV-infected women in the United States in the era of highly active antiretroviral therapy (HAART)
    Bansil, Pooja
    Jamieson, Denise J.
    Posner, Samuel F.
    Kourtis, Athena P.
    [J]. JOURNAL OF WOMENS HEALTH, 2007, 16 (02) : 159 - 162
  • [6] Prevalence of Metabolic Abnormalities in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy and Antiretroviral-Naive Patients
    Ramezani, A.
    Mohraz, M.
    Jam, S.
    Banifazl, M.
    Aghakhani, A.
    Eslamifar, A.
    Gachkar, L.
    Yaghmaie, F.
    Nemati, K.
    Velayati, A. A.
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2008, 12 : E200 - E200
  • [7] Highly active antiretroviral therapy (HAART) in a cohort of antiretroviral-naive HIV-infected patients after a long followup
    Guardiola, JM
    Madrid, F
    Montero, F
    Barceló, M
    Domingo, P
    Vázquez, G
    [J]. AIDS, 1998, 12 : S42 - S42
  • [8] Antiretroviral therapy in HIV-Infected pregnant women and their infants: Current interventions and challenges
    Shannon, M
    [J]. JOURNAL OF PERINATAL & NEONATAL NURSING, 2002, 16 (02) : 1 - 25
  • [9] Helminth infections and malaria in HIV-infected pregnant women on antiretroviral therapy in Rwanda
    Ivan, E. I.
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2014, 21 : 279 - 279
  • [10] Time to clinically significant viral suppression in HIV-infected pregnant women
    Wright, RL
    Einstein, F
    Trentacoste, S
    Van Eerden, P
    Bebbington, M
    Merkatz, IR
    Bernstein, PS
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2003, 189 (06) : S102 - S102